VijayPD Ceutical revenue doubles, profit rises 39% in H1
Key highlights
- VijayPD Ceutical reported Rs 105.21 crore of revenue from operations for the half year ended September 30, 2026, versus Rs 51.33 crore a year earlier.
- Profit attributable to VijayPD Ceutical owners rose 39% to Rs 3.36 crore from Rs 2.42 crore.
- VijayPD Ceutical’s September 2026 results include two subsidiaries, while the September 2025 comparator is standalone.
- VijayPD Ceutical’s trade receivables rose to Rs 67.58 crore at September 30, 2026 from Rs 31.64 crore at March 31, 2026.
powered by IRIS

VijayPD Ceutical Limited reported consolidated revenue from operations of Rs 105.21 crore for the half year ended September 30, 2026, compared with Rs 51.33 crore in the prior-year period, while profit attributable to owners rose 39% to Rs 3.36 crore. The earlier comparison is standalone, rather than consolidated, because the company had no subsidiaries then.
Know Vijaypd Ceutical inside out
Results, valuation, peers and who's buying, in one view.
How did VijayPD Ceutical perform in the first half?
VijayPD Ceutical recorded revenue from operations of Rs 105.21 crore for the half year ended September 30, 2026, an increase of Rs 53.88 crore, or about 105%, from Rs 51.33 crore in the half year ended September 30, 2025. Total income rose to Rs 105.67 crore from Rs 51.66 crore, with other income increasing to Rs 46.07 lakh from Rs 32.26 lakh.
Profit attributable to owners of the parent increased to Rs 3.36 crore from Rs 2.42 crore, a rise of Rs 94.12 lakh, or about 39%. Profit before tax rose to Rs 4.60 crore from Rs 3.34 crore, while total tax expense increased to Rs 1.25 crore from Rs 92.88 lakh. The latest result also included Rs 1.10 lakh of profit attributable to minority interest.
VijayPD Ceutical also reported higher revenue and profit than in the immediately preceding half year ended March 31, 2026. Revenue from operations was Rs 48.90 crore in that period and profit attributable to owners was Rs 2.59 crore, against Rs 105.21 crore and Rs 3.36 crore respectively in the September 2026 half year. Basic and diluted earnings per share were Rs 1.72, compared with Rs 1.55 in the March 2026 half year.
The company stated that earnings per share for the half year were not annualised. Paid-up equity share capital was unchanged from March 31, 2026 at Rs 19.53 crore, while it was Rs 14.03 crore in the September 2025 comparative period. This change in share capital is relevant when comparing the reported earnings-per-share figures across the periods.
Is VijayPD Ceutical’s year-on-year comparison fully comparable?
No, VijayPD Ceutical’s September 2026 comparison with September 2025 is not fully comparable because the current figures are consolidated while the earlier figures are standalone. The company said it had no subsidiary in the corresponding half year ended September 30, 2025 or in the year ended March 31, 2025, and therefore did not need to prepare consolidated results for those periods.
The September 2026 results include Siddharth Drugs Private Limited, a 100% subsidiary, and M/s Zen Pharmaceutical, a 95% subsidiary. As a result, the Rs 105.21 crore of current-period revenue incorporates the businesses of these subsidiaries, whereas the Rs 51.33 crore comparator reflects VijayPD Ceutical’s standalone operations. The reported 105% rise therefore also reflects a changed reporting perimeter.
VijayPD Ceutical’s board approved the consolidated unaudited results on November 14, 2026, after review by its Audit Committee. J D Shah Associates issued a limited review report dated November 14, 2026, stating that nothing had come to its attention to suggest that the results did not make required disclosures or contained a material misstatement.
The results were prepared under Accounting Standard 25 for interim financial reporting, as stated in the auditor’s report. The limited review is narrower in scope than an audit, and the auditor did not express an audit opinion. VijayPD Ceutical reported the consolidated results under Regulation 33 of the Securities and Exchange Board of India’s listing disclosure regulations.
Got a follow-up? Ask IRIS
What drove costs and profit at VijayPD Ceutical?
VijayPD Ceutical’s total expenses rose about 109% to Rs 101.03 crore in the September 2026 half year from Rs 48.31 crore a year earlier, compared with a 105% increase in total income. Purchases of stock-in-trade were the largest cost item at Rs 97.29 crore, up from Rs 42.62 crore. The group said it is exclusively engaged in pharmaceutical trading and reported no separate segment under Accounting Standard 17.
Employee benefits expense rose to Rs 2.17 crore from Rs 1.22 crore, finance costs increased to Rs 1.67 crore from Rs 1.06 crore, and other expenses rose to Rs 2.02 crore from Rs 72.59 lakh. Depreciation and amortisation expense was Rs 44.21 lakh, compared with Rs 27.76 lakh. These costs were partly offset by a Rs 2.56 crore credit from changes in inventories, against a Rs 2.41 crore expense in the prior-year half.
Profit before exceptional items and tax was Rs 4.64 crore, compared with Rs 3.34 crore in the September 2025 half year. VijayPD Ceutical then recorded a prior-period expense of Rs 4.05 lakh, which reduced profit before tax to Rs 4.60 crore. No prior-period expense was reported in the September 2025 comparison.
Current tax was Rs 1.14 crore, compared with Rs 85.96 lakh a year earlier, while deferred tax was an expense of Rs 10.62 lakh after a deferred-tax credit of Rs 77,000 in the prior-year half. Total tax therefore increased by Rs 31.73 lakh to Rs 1.25 crore. After tax and the Rs 1.10 lakh minority-interest allocation, owners’ profit was Rs 3.36 crore.
What changed in VijayPD Ceutical’s balance sheet and cash flow?
VijayPD Ceutical’s total assets increased to Rs 145.40 crore at September 30, 2026 from Rs 100.70 crore at March 31, 2026. Trade receivables rose to Rs 67.58 crore from Rs 31.64 crore, inventories increased to Rs 21.37 crore from Rs 12.46 crore, and short-term loans and advances rose to Rs 25.93 crore from Rs 10.01 crore.
Cash and cash equivalents fell to Rs 1.95 crore at September 30, 2026 from Rs 17.52 crore at March 31, 2026. The consolidated cash-flow statement recorded net cash used in operating activities of Rs 25.14 crore during the half year, compared with Rs 8.78 crore used in operating activities during the year ended March 31, 2026.
The half-year operating cash movement included a Rs 35.94 crore increase in trade receivables, a Rs 15.92 crore increase in loans and advances, and a Rs 8.90 crore increase in inventories. These outflows were partly offset by a Rs 27.02 crore increase in trade payables and a Rs 1.93 crore increase in other liabilities and provisions. Cash generated from operations before direct taxes was negative Rs 25.37 crore.
On the liabilities side, short-term borrowings rose to Rs 40.72 crore at September 30 from Rs 32.32 crore at March 31, while long-term borrowings rose to Rs 8.41 crore from Rs 4.39 crore. Net financing cash inflow was Rs 10.67 crore during the half year, including Rs 8.40 crore from net short-term borrowing movements and Rs 4.03 crore of long-term borrowings. Net cash used in investing activities was Rs 1.10 crore, including Rs 2.75 crore spent on property, plant, equipment and capital work in progress.
Conclusion
VijayPD Ceutical reported a substantial increase in first-half revenue and a 39% rise in profit attributable to owners, with purchases of stock-in-trade rising to Rs 97.29 crore as revenue reached Rs 105.21 crore. The reported year-on-year growth needs to be read alongside the changed reporting basis: September 2026 includes two subsidiaries, while the September 2025 figures are standalone.
The next filings will show whether trade receivables of Rs 67.58 crore, short-term loans and advances of Rs 25.93 crore, and short-term borrowings of Rs 40.72 crore change after September 30, 2026. They will also show whether operating cash flow improves from the Rs 25.14 crore outflow reported for the half year, as the filing does not disclose a revenue target, profit target or date for the next results announcement.


